Clinical trial
Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or…
NCT00068393 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00068393 |
|---|---|
| Title | Doxorubicin and Gemcitabine in Treating Patients With Locally Recurrent or Metastatic Unresectable Renal Cell Carcinoma |
| Official title | Phase II Trial of Doxorubicin and Gemcitabine in Metastatic Renal Cell Carcinoma With Sarcomatoid Features |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Metastatic Renal Cell Carcinoma, Renal Cell Carcinoma With Sarcomatoid Features |
| Intervention type | Drug |
| Interventions | Doxorubicin, Gemcitabine, G-CSF (granulocyte-colony stimulating factor), Neulasta |
| Enrollment | 39 |
| Start date | Feb 24, 2004 |
| Primary completion | Jun 1, 2009 |
| Completion | May 1, 2011 |
| First posted | Sep 11, 2003 |
| Last update posted | Jul 7, 2023 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: